Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A depression rating scale for schizophrenics.

D Addington1, J Addington, B Schissel

  • 1University of Calgary, Department of Psychiatry, Foothills Hospital, Calgary, Canada.

Schizophrenia Research
|July 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.

Schizophrenia research·2024
Same author

Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.

Schizophrenia research·2020
Same author

Childhood trauma and cognitive functioning in individuals at clinical high risk (CHR) for psychosis.

Development and psychopathology·2020
Same author

Neurocognitive predictors of metacognition in individuals at clinical high risk for psychosis.

Behavioural and cognitive psychotherapy·2019
Same author

The Early Psychosis Screener for Internet (EPSI)-SR: Predicting 12 month psychotic conversion using machine learning.

Schizophrenia research·2019
Same author

Longitudinal changes in social cognition in individuals at clinical high risk for psychosis: An outcome based analysis.

Schizophrenia research·2018
Same journal

Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.

Schizophrenia research·2026
Same journal

FL-SDGIN: A federated graph learning approach for schizophrenia diagnosis integrating static and dynamic brain functional networks.

Schizophrenia research·2026
Same journal

Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.

Schizophrenia research·2026
Same journal

Converting negative symptom dimension scores across SANS and PANSS.

Schizophrenia research·2026
Same journal

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026
Same journal

One social interaction after another: Dynamic modeling of social experience in schizophrenia.

Schizophrenia research·2026
See all related articles

A new depression rating scale was developed for individuals with schizophrenia, improving upon existing measures. This scale demonstrates strong reliability for assessing depression in psychotic populations.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Psychometrics

Background:

  • Existing depression scales are often unsuitable for patients with psychotic disorders.
  • Schizophrenia frequently co-occurs with depressive symptoms, necessitating accurate assessment tools.

Purpose of the Study:

  • To develop and validate a new rating scale for measuring depression specifically in schizophrenia patients.
  • To adapt and select items from established scales (Hamilton Depression Rating Scale, Present State Examination) for this purpose.

Main Methods:

  • A three-stage selection process involving factor analysis, internal consistency measures, and face validity.
  • Application of the developed scale to 50 acutely ill schizophrenia patients meeting DSM-III criteria.
  • Assessment at two distinct time points to evaluate reliability.

Related Experiment Videos

Main Results:

  • A novel eleven-item scale was created by selecting items from the Hamilton Depression Rating Scale and the Present State Examination.
  • The scale exhibited high internal consistency, with Cronbach's alpha values of 0.84 at time one and 0.89 at time two.
  • The developed instrument proved superior for measuring depression in schizophrenia.

Conclusions:

  • The new rating scale is a reliable and valid instrument for assessing depression in schizophrenia.
  • This tool addresses the limitations of existing scales in psychotic populations.
  • It offers a more appropriate method for clinical and research settings involving schizophrenia and depression.